Logo image of TLSI

TRISALUS LIFE SCIENCES INC (TLSI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TLSI - US89680M1018 - Common Stock

6.7 USD
+0.27 (+4.2%)
Last: 12/4/2025, 8:00:00 PM
6.7 USD
0 (0%)
After Hours: 12/4/2025, 8:00:00 PM
Fundamental Rating

2

Overall TLSI gets a fundamental rating of 2 out of 10. We evaluated TLSI against 534 industry peers in the Biotechnology industry. Both the profitability and financial health of TLSI have multiple concerns. While showing a medium growth rate, TLSI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TLSI has reported negative net income.
In the past year TLSI has reported a negative cash flow from operations.
In multiple years TLSI reported negative net income over the last 5 years.
In the past 5 years TLSI always reported negative operating cash flow.
TLSI Yearly Net Income VS EBIT VS OCF VS FCFTLSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -82.73%, TLSI is not doing good in the industry: 68.35% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -82.73%
ROE N/A
ROIC N/A
ROA(3y)-123.26%
ROA(5y)-73.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TLSI Yearly ROA, ROE, ROICTLSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

With an excellent Gross Margin value of 84.67%, TLSI belongs to the best of the industry, outperforming 86.70% of the companies in the same industry.
TLSI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLSI Yearly Profit, Operating, Gross MarginsTLSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

TLSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLSI has been increased compared to 1 year ago.
Compared to 1 year ago, TLSI has a worse debt to assets ratio.
TLSI Yearly Shares OutstandingTLSI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
TLSI Yearly Total Debt VS Total AssetsTLSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -7.57, we must say that TLSI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.57, TLSI is not doing good in the industry: 68.54% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.57
ROIC/WACCN/A
WACC8.55%
TLSI Yearly LT Debt VS Equity VS FCFTLSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

TLSI has a Current Ratio of 4.08. This indicates that TLSI is financially healthy and has no problem in meeting its short term obligations.
TLSI has a Current ratio of 4.08. This is comparable to the rest of the industry: TLSI outperforms 49.63% of its industry peers.
A Quick Ratio of 3.68 indicates that TLSI has no problem at all paying its short term obligations.
TLSI has a Quick ratio (3.68) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.08
Quick Ratio 3.68
TLSI Yearly Current Assets VS Current LiabilitesTLSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.39% over the past year.
TLSI shows a strong growth in Revenue. In the last year, the Revenue has grown by 58.99%.
EPS 1Y (TTM)47.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.33%
Revenue 1Y (TTM)58.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%57.38%

3.2 Future

TLSI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.99% yearly.
The Revenue is expected to grow by 38.95% on average over the next years. This is a very strong growth
EPS Next Y38.95%
EPS Next 2Y40.83%
EPS Next 3Y30.99%
EPS Next 5YN/A
Revenue Next Year55%
Revenue Next 2Y54.53%
Revenue Next 3Y48.27%
Revenue Next 5Y38.95%

3.3 Evolution

TLSI Yearly Revenue VS EstimatesTLSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
TLSI Yearly EPS VS EstimatesTLSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TLSI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLSI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLSI Price Earnings VS Forward Price EarningsTLSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 -100 -200 -300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLSI Per share dataTLSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

TLSI's earnings are expected to grow with 30.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.83%
EPS Next 3Y30.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TLSI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRISALUS LIFE SCIENCES INC

NASDAQ:TLSI (12/4/2025, 8:00:00 PM)

After market: 6.7 0 (0%)

6.7

+0.27 (+4.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-24 2026-03-24/bmo
Inst Owners17.25%
Inst Owner Change12.59%
Ins Owners16.69%
Ins Owner Change9.05%
Market Cap334.73M
Revenue(TTM)29.43M
Net Income(TTM)-34.18M
Analysts83.08
Price Target11.58 (72.84%)
Short Float %2.22%
Short Ratio5.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-47.45%
Min EPS beat(2)-73.8%
Max EPS beat(2)-21.11%
EPS beat(4)1
Avg EPS beat(4)-13.12%
Min EPS beat(4)-73.8%
Max EPS beat(4)66%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.14%
Min Revenue beat(2)-0.53%
Max Revenue beat(2)2.81%
Revenue beat(4)1
Avg Revenue beat(4)-0.12%
Min Revenue beat(4)-2.55%
Max Revenue beat(4)2.81%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.24%
PT rev (3m)0.39%
EPS NQ rev (1m)-4.87%
EPS NQ rev (3m)-3.35%
EPS NY rev (1m)2.93%
EPS NY rev (3m)0.68%
Revenue NQ rev (1m)-0.86%
Revenue NQ rev (3m)0.39%
Revenue NY rev (1m)0.34%
Revenue NY rev (3m)0.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.3
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.31
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0.72
BVpS-0.39
TBVpS-0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.73%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.67%
FCFM N/A
ROA(3y)-123.26%
ROA(5y)-73.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 124.96%
Cap/Sales 2.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.08
Quick Ratio 3.68
Altman-Z -7.57
F-Score3
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.33%
EPS Next Y38.95%
EPS Next 2Y40.83%
EPS Next 3Y30.99%
EPS Next 5YN/A
Revenue 1Y (TTM)58.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%57.38%
Revenue Next Year55%
Revenue Next 2Y54.53%
Revenue Next 3Y48.27%
Revenue Next 5Y38.95%
EBIT growth 1Y40.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.38%
EBIT Next 3Y28.55%
EBIT Next 5Y21.3%
FCF growth 1Y-38.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.19%
OCF growth 3YN/A
OCF growth 5YN/A

TRISALUS LIFE SCIENCES INC / TLSI FAQ

What is the fundamental rating for TLSI stock?

ChartMill assigns a fundamental rating of 2 / 10 to TLSI.


What is the valuation status for TLSI stock?

ChartMill assigns a valuation rating of 1 / 10 to TRISALUS LIFE SCIENCES INC (TLSI). This can be considered as Overvalued.


What is the profitability of TLSI stock?

TRISALUS LIFE SCIENCES INC (TLSI) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for TLSI stock?

The Earnings per Share (EPS) of TRISALUS LIFE SCIENCES INC (TLSI) is expected to grow by 38.95% in the next year.